News
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Immunic Inc. highlights its 2025 accomplishments & upcoming milestones including phase 3 trials for Vidofludimus Calcium in relapsing Multiple Sclerosis, positive data in Progressive MS, & potential for IMU-856 in weight management -
-
-
COMMUNIQUÉ DE PRESSE
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
Immunic to participate in the 8th Annual Evercore ISI Healthcare Conference in December. Dr. Daniel Vitt to speak at fireside chat on novel oral therapies for neurologic and gastrointestinal diseases -
-
-
COMMUNIQUÉ DE PRESSE
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q3 2025 financial results and provides corporate update, highlighting vidofludimus calcium's therapeutic potential in multiple sclerosis. Phase 3 ENSURE trial data expected by 2026 -